With regard to the effectiveness of filgotinib, the FINCH 1 trial showed that filgotinib 200 mg/day + MTX was non-inferior to adalimumab + MTX in terms of DAS28-CRP in RA patients with an inadequate response to MTX [6]. Here, CRP is linked to rheumatoid arthritis.